全球生物製药契约製造市场规模、份额、趋势和成长分析报告（2026-2034）

预计生物製药契约製造市场将从 2025 年的 497.6 亿美元成长到 2034 年的 1,319 亿美元，2026 年至 2034 年的复合年增长率为 11.44%。

由于对生物製药、生物相似药和复杂治疗产品的需求不断增长，全球生物製药契约製造市场正在快速扩张。製药公司越来越多地将生产流程外包给契约製造组织（CMO），以降低成本并简化营运。这一趋势显着推动了各个地区市场的成长。

关键成长要素包括慢性病盛行率上升、研发投入增加、生物製药生产日益复杂。契约製造生产商是重要的合作伙伴，可提供专业知识、先进技术和法规支援。此外，对灵活且扩充性的生产能力的需求不断增长，也进一步推动了市场需求。

未来，由于生物製程的创新和个人化医疗的兴起，市场预计将显着增长。基因疗法和先进生物製药的发展将为合约生产企业（CMO）创造新的机会。随着製药公司持续专注于创新和效率提升，契约製造仍将是该产业至关重要的策略要素。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球生物製药契约製造市场：依来源划分

• 市场分析、洞察与预测
• 哺乳动物起源
• 非哺乳动物

第五章：全球生物製药契约製造市场：依服务类型划分

• 市场分析、洞察与预测
• 製程开发
• 填充和表面处理工程
• 分析和品管(QC) 测试
• 包装和标籤
• 其他的

第六章 全球生物製药契约製造市场：依药物类型划分

• 市场分析、洞察与预测
• 生物製药
• 生物相似药

第七章 全球生物製药契约製造市场：按类型划分

• 市场分析、洞察与预测
• 原料药
• 已完成的药品

第八章：全球生物製药契约製造市场：依企业规模划分

• 市场分析、洞察与预测
• 临床阶段
• 商业

第九章：全球生物製药契约製造市场：依治疗领域划分

• 市场分析、洞察与预测
• 肿瘤学
• 自体免疫疾病
• 感染疾病
• 心血管疾病
• 代谢性疾病
• 神经病学
• 其他的

第十章：全球生物製药契约製造市场：按地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第十一章 竞争格局

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十二章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Boehringer Ingelheim GmbH
  • Lonza
  • Inno Biologics Sdn Bhd
  • Rentschler Biotechnologie GmbH
  • JRS PHARMA
  • AGC Biologics
  • ProBioGen
  • FUJIFILM Diosynth Biotechnologies USA Inc
  • Toyobo Co. Ltd
  • Samsung Biologics
  • Thermo Fisher Scientific Inc
  • Binex Co. Ltd
  • WuXi Biologics
  • AbbVie Inc

The Biopharmaceuticals Contract Manufacturing Market size is expected to reach USD 131.90 Billion in 2034 from USD 49.76 Billion (2025) growing at a CAGR of 11.44% during 2026-2034.

The global biopharmaceuticals contract manufacturing market is witnessing rapid expansion due to the increasing demand for biologics, biosimilars, and complex therapeutic products. Pharmaceutical companies are increasingly outsourcing manufacturing processes to contract manufacturing organizations (CMOs) to reduce costs and streamline operations. This trend has significantly contributed to the growth of the market across various regions.

Major growth drivers include the rising prevalence of chronic diseases, increased investment in research and development, and the complexity of biologic drug production. Contract manufacturers provide specialized expertise, advanced technologies, and regulatory support, making them valuable partners. Additionally, the need for flexible and scalable production capabilities is further boosting market demand.

Looking ahead, the market is poised for substantial growth driven by innovations in bioprocessing and the emergence of personalized medicine. The development of gene therapies and advanced biologics will create new opportunities for CMOs. As pharmaceutical companies continue to focus on innovation and efficiency, contract manufacturing will remain a key strategic component in the industry.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Source

• Mammalian
• Non-mammalian

By Service

• Process Development
• Fill & Finish Operations
• Analytical & QC studies
• Packaging & Labelling
• Others

By Drug Type

• Biologics
• Biosimilars

By Type

• Drug Substance
• Finished Drug Product

By Scale of Operation

• Clinical
• Commercial

By Therapeutic Area

• Oncology
• Autoimmune Diseases
• Infectious Diseases
• Cardiovascular Diseases
• Metabolic Diseases
• Neurology
• Others

COMPANIES PROFILED

• Boehringer Ingelheim GmbH, Lonza, Inno Biologics Sdn Bhd, Rentschler Biotechnologie GmbH, JRS PHARMA, AGC Biologics, ProBioGen, FUJIFILM Diosynth Biotechnologies USA Inc, Toyobo Co Ltd, Samsung Biologics, Thermo Fisher Scientific Inc, Binex Co Ltd, WuXi Biologics, AbbVie Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET: BY SOURCE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Source
• 4.2. Mammalian Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Non-mammalian Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET: BY SERVICE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Service
• 5.2. Process Development Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Fill & Finish Operations Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Analytical & QC studies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Packaging & Labelling Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET: BY DRUG TYPE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Drug Type
• 6.2. Biologics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Biosimilars Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET: BY TYPE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Type
• 7.2. Drug Substance Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Finished Drug Product Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET: BY SCALE OF OPERATION 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Scale Of Operation
• 8.2. Clinical Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Commercial Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET: BY THERAPEUTIC AREA 2022-2034 (USD MN)

• 9.1. Market Analysis, Insights and Forecast Therapeutic Area
• 9.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.3. Autoimmune Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.4. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.5. Cardiovascular Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.6. Metabolic Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.7. Neurology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 10. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET: BY REGION 2022-2034 (USD MN)

• 10.1. Regional Outlook
• 10.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.2.1 By Source
  • 10.2.2 By Service
  • 10.2.3 By Drug Type
  • 10.2.4 By Type
  • 10.2.5 By Scale Of Operation
  • 10.2.6 By Therapeutic Area
  • 10.2.7 United States
  • 10.2.8 Canada
  • 10.2.9 Mexico
• 10.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.3.1 By Source
  • 10.3.2 By Service
  • 10.3.3 By Drug Type
  • 10.3.4 By Type
  • 10.3.5 By Scale Of Operation
  • 10.3.6 By Therapeutic Area
  • 10.3.7 United Kingdom
  • 10.3.8 France
  • 10.3.9 Germany
  • 10.3.10 Italy
  • 10.3.11 Russia
  • 10.3.12 Rest Of Europe
• 10.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.4.1 By Source
  • 10.4.2 By Service
  • 10.4.3 By Drug Type
  • 10.4.4 By Type
  • 10.4.5 By Scale Of Operation
  • 10.4.6 By Therapeutic Area
  • 10.4.7 India
  • 10.4.8 Japan
  • 10.4.9 South Korea
  • 10.4.10 Australia
  • 10.4.11 South East Asia
  • 10.4.12 Rest Of Asia Pacific
• 10.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.5.1 By Source
  • 10.5.2 By Service
  • 10.5.3 By Drug Type
  • 10.5.4 By Type
  • 10.5.5 By Scale Of Operation
  • 10.5.6 By Therapeutic Area
  • 10.5.7 Brazil
  • 10.5.8 Argentina
  • 10.5.9 Peru
  • 10.5.10 Chile
  • 10.5.11 Rest of Latin America
• 10.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.6.1 By Source
  • 10.6.2 By Service
  • 10.6.3 By Drug Type
  • 10.6.4 By Type
  • 10.6.5 By Scale Of Operation
  • 10.6.6 By Therapeutic Area
  • 10.6.7 Saudi Arabia
  • 10.6.8 UAE
  • 10.6.9 Israel
  • 10.6.10 South Africa
  • 10.6.11 Rest of the Middle East And Africa

Chapter 11. COMPETITIVE LANDSCAPE

• 11.1. Recent Developments
• 11.2. Company Categorization
• 11.3. Supply Chain & Channel Partners (based on availability)
• 11.4. Market Share & Positioning Analysis (based on availability)
• 11.5. Vendor Landscape (based on availability)
• 11.6. Strategy Mapping

Chapter 12. COMPANY PROFILES OF GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING INDUSTRY

• 12.1. Top Companies Market Share Analysis
• 12.2. Company Profiles
  • 12.2.1 Boehringer Ingelheim GmbH
  • 12.2.2 Lonza
  • 12.2.3 Inno Biologics Sdn Bhd
  • 12.2.4 Rentschler Biotechnologie GmbH
  • 12.2.5 JRS PHARMA
  • 12.2.6 AGC Biologics
  • 12.2.7 ProBioGen
  • 12.2.8 FUJIFILM Diosynth Biotechnologies U.S.A. Inc
  • 12.2.9 Toyobo Co. Ltd
  • 12.2.10 Samsung Biologics
  • 12.2.11 Thermo Fisher Scientific Inc
  • 12.2.12 Binex Co. Ltd
  • 12.2.13 WuXi Biologics
  • 12.2.14 AbbVie Inc